| Attribute |
Value |
| 52 Week Change |
0.073580265 |
| Address1 |
1,350 Old Bayshore Highway |
| Address2 |
Suite 400 |
| All Time High |
34.617245 |
| All Time Low |
3.481064 |
| Ask |
27.62 |
| Ask Size |
2 |
| Audit Risk |
6 |
| Average Daily Volume10 Day |
898,540 |
| Average Daily Volume3 Month |
824,275 |
| Average Volume |
824,275 |
| Average Volume10Days |
898,540 |
| Beta |
0.344 |
| Bid |
15.69 |
| Bid Size |
2 |
| Board Risk |
8 |
| Book Value |
18.178 |
| City |
Burlingame |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
6 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
21.925 |
| Current Ratio |
21.134 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
21.925 |
| Day Low |
21.56 |
| Debt To Equity |
24.702 |
| Display Name |
Innoviva |
| Dividend Date |
1,443,571,200 |
| Earnings Timestamp End |
1,785,960,000 |
| Earnings Timestamp Start |
1,785,960,000 |
| Ebitda |
192,700,000 |
| Ebitda Margins |
0.45806 |
| Enterprise To Ebitda |
6.871 |
| Enterprise To Revenue |
3.147 |
| Enterprise Value |
1,324,089,216 |
| Eps Current Year |
1.91 |
| Eps Forward |
2.21 |
| Eps Trailing Twelve Months |
6.26 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,441,670,400 |
| Exchange |
NMS |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
22.4584 |
| Fifty Day Average Change |
-0.5334015 |
| Fifty Day Average Change Percent |
-0.023750644 |
| Fifty Two Week Change Percent |
7.3580265 |
| Fifty Two Week High |
25.15 |
| Fifty Two Week High Change |
-3.2250004 |
| Fifty Two Week High Change Percent |
-0.12823063 |
| Fifty Two Week Low |
16.52 |
| Fifty Two Week Low Change |
5.404999 |
| Fifty Two Week Low Change Percent |
0.3271791 |
| Fifty Two Week Range |
16.52 - 25.15 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,096,983,000,000 |
| Float Shares |
69,201,607 |
| Forward Eps |
2.21 |
| Forward P E |
9.920814 |
| Free Cashflow |
105,171,624 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
159 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,782,864,000 |
| Gross Margins |
0.74100995 |
| Gross Profits |
311,736,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.00989 |
| Held Percent Institutions |
1.0792401 |
| Implied Shares Outstanding |
73,808,749 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Dividend Date |
1,441,670,400 |
| Last Dividend Value |
0.25 |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,401,753,600 |
| Last Split Factor |
1,241:1000 |
| Long Business Summary |
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. |
| Long Name |
Innoviva, Inc. |
| Market |
us_market |
| Market Cap |
1,618,256,768 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_24362 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
504,344,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
1,604,602,203 |
| Number Of Analyst Opinions |
4 |
| Open |
21.765 |
| Operating Cashflow |
183,595,008 |
| Operating Margins |
0.40108 |
| Overall Risk |
6 |
| Payout Ratio |
0.0 |
| Peg Ratio |
0.32 |
| Phone |
650 238 9600 |
| Previous Close |
21.74 |
| Price Eps Current Year |
11.479057 |
| Price Hint |
2 |
| Price To Book |
1.2061282 |
| Price To Sales Trailing12 Months |
3.846673 |
| Profit Margins |
1.19885 |
| Quick Ratio |
19.272 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
0.18499947 |
| Regular Market Change Percent |
0.85096353 |
| Regular Market Day High |
21.925 |
| Regular Market Day Low |
21.56 |
| Regular Market Day Range |
21.56 - 21.925 |
| Regular Market Open |
21.765 |
| Regular Market Previous Close |
21.74 |
| Regular Market Price |
21.925 |
| Regular Market Time |
1,784,123,715 |
| Regular Market Volume |
33,770 |
| Return On Assets |
0.06722 |
| Return On Equity |
0.50725 |
| Revenue Growth |
0.106 |
| Revenue Per Share |
5.988 |
| Sand P52 Week Change |
0.2043345 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
4 |
| Shares Outstanding |
73,808,749 |
| Shares Percent Shares Out |
0.09 |
| Shares Short |
6,645,977 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
5,859,814 |
| Short Name |
Innoviva, Inc. |
| Short Percent Of Float |
0.121300004 |
| Short Ratio |
7.09 |
| Source Interval |
15 |
| State |
CA |
| Symbol |
INVA |
| Target High Price |
46.0 |
| Target Low Price |
18.0 |
| Target Mean Price |
35.5 |
| Target Median Price |
39.0 |
| Total Cash |
611,931,008 |
| Total Cash Per Share |
8.291 |
| Total Debt |
331,417,984 |
| Total Revenue |
420,689,984 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
6.26 |
| Trailing P E |
3.5023959 |
| Trailing Peg Ratio |
0.3169 |
| Triggerable |
1 |
| Two Hundred Day Average |
21.2835 |
| Two Hundred Day Average Change |
0.64149857 |
| Two Hundred Day Average Change Percent |
0.030140651 |
| Type Disp |
Equity |
| Volume |
33,770 |
| Website |
https://www.inva.com |
| Zip |
94,010 |